<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The deletion (5q) karyotype [del (5q)] in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is considered a good risk feature, while the impact of del (5q) combined with other karyotypic abnormalities [del (5q)+] is less well defined </plain></SENT>
<SENT sid="1" pm="."><plain>We analysed the outcome of haematopoietic cell transplants (HCT) in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with del (5q) or del (5q)+ </plain></SENT>
<SENT sid="2" pm="."><plain>Fifty-seven patients, aged 6-72 years, with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and del (5q) abnormalities received HCT from related (n = 32) or unrelated (n = 25) donors </plain></SENT>
<SENT sid="3" pm="."><plain>By French-American-British (FAB) criteria, 27 patients had refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA), 10 RA with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), eight <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) and 12 <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> evolving from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (tAML) </plain></SENT>
<SENT sid="4" pm="."><plain>Non-relapse mortality at 1-year post-transplantation was 30% for del (5q) and 38% for del (5q)+ patients </plain></SENT>
<SENT sid="5" pm="."><plain>Relapse occurred in one of 20 del (5q) patients and 15 of 37 del (5q)+ patients (P = 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>After adjusting for del (5q) status, blast count (&lt;5%) was the only factor significantly associated with relapse-free survival </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with del (5q), either as a '<z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e>' or with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in general, had better outcomes than did patients with del (5q)+ </plain></SENT>
<SENT sid="8" pm="."><plain>The indication for transplantation in patients with del (5q) was generally severe cytopenias, compared with disease progression to a more advanced FAB stage in patients with del (5q)+ </plain></SENT>
<SENT sid="9" pm="."><plain>Conceivably, outcome for patients with del (5q)+ would be improved with transplantation earlier in the disease course </plain></SENT>
</text></document>